Subtopic Deep Dive
WHO Classification of Lymphoid Neoplasms CLL
Research Guide
What is WHO Classification of Lymphoid Neoplasms CLL?
The WHO Classification of Lymphoid Neoplasms for CLL defines diagnostic criteria for chronic lymphocytic leukemia and small lymphocytic lymphoma based on morphology, immunophenotype, genetics, and clinical features in the 5th edition (2022).
The 2016 and 2022 WHO updates refine CLL distinctions from cyclin D1-negative entities and monoclonal B-cell lymphocytosis. Key criteria include CD5+, CD23+ immunophenotype and IGHV mutation status (Alaggio et al., 2022, 3291 citations). Over 50 papers in the provided lists address classification impacts on CLL incidence and therapy.
Why It Matters
WHO CLL criteria determine trial eligibility for ibrutinib in relapsed cases (Byrd et al., 2013, 2228 citations) and rituximab regimens. Accurate classification using ZAP-70 as IGHV surrogate improves prognosis (Crespo et al., 2003, 1329 citations). Incidence studies by subtype guide epidemiologic research (Morton et al., 2005, 1671 citations; Sant et al., 2010, 943 citations).
Key Research Challenges
Distinguishing SLL from CLL
Morphologic overlap between small lymphocytic lymphoma and CLL requires precise lymph node versus peripheral blood assessment. Immunophenotyping standardization remains inconsistent across labs (van Dongen et al., 2012, 887 citations). EuroFlow panels aid but need validation in WHO contexts.
IGHV Mutation Status Assessment
ZAP-70 expression serves as surrogate but correlates imperfectly with IGHV mutations in diverse cohorts (Crespo et al., 2003, 1329 citations). Flow cytometry thresholds vary, complicating prognostication. Genetic testing scalability limits routine use.
Cyclin D1-Negative Entity Classification
WHO updates address cyclin D1-negative mantle cell-like lymphomas mimicking CLL. Incidence patterns by subtype reveal diagnostic gaps (Morton et al., 2005, 1671 citations). Multidisciplinary integration of morphology and genetics poses practical hurdles.
Essential Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
Rita Alaggio, Catalina Amador, Ioannis Anagnostopoulos et al. · 2022 · Leukemia · 3.3K citations
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd, Richard R. Furman, Steven Coutré et al. · 2013 · New England Journal of Medicine · 2.2K citations
Ibrutinib was associated with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions. (...
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
Elı́as Campo, Steven H. Swerdlow, Nancy L. Harris et al. · 2011 · Blood · 2.0K citations
Abstract The World Health Organization classification of lymphoid neoplasms updated in 2008 represents a worldwide consensus on the diagnosis of these tumors and is based on the recognition of dist...
Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001
Lindsay M. Morton, Sophia Wang, Susan S. Devesa et al. · 2005 · Blood · 1.7K citations
Abstract Because the causes of most lymphoid neoplasms remain unknown, comparison of incidence patterns by disease subtype may provide critical clues for future etiologic investigations. We therefo...
ZAP-70 Expression as a Surrogate for Immunoglobulin-Variable-Region Mutations in Chronic Lymphocytic Leukemia
Marta Crespo, Francesc Bosch, Neus Villamor et al. · 2003 · New England Journal of Medicine · 1.3K citations
The mutational status of immunoglobulin heavy-chain variable-region (IgVH ) genes in the leukemic cells of chronic lymphocytic leukemia (CLL) is an important prognostic factor in the disease. We in...
Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project
Milena Sant, Claudia Allemani, Carmen Ţereanu et al. · 2010 · Blood · 943 citations
Abstract Changing definitions and classifications of hematologic malignancies (HMs) complicate incidence comparisons. HAEMACARE classified HMs into groupings consistent with the latest World Health...
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes
Jacques J. M. van Dongen, Ludovic Lhermitte, Sebastian Böttcher et al. · 2012 · Leukemia · 887 citations
Reading Guide
Foundational Papers
Start with Campo et al. (2011, 1957 citations) for 2008 WHO baseline, then Crespo et al. (2003, 1329 citations) for ZAP-70/IGHV prognostic role in CLL diagnostics.
Recent Advances
Prioritize Alaggio et al. (2022, 3291 citations) for 5th edition lymphoid neoplasms updates specific to CLL/SLL distinctions.
Core Methods
Morphology, flow cytometry (EuroFlow panels, van Dongen et al., 2012), genetics (IGHV sequencing, ZAP-70 expression), incidence epidemiology (Morton et al., 2005).
How PapersFlow Helps You Research WHO Classification of Lymphoid Neoplasms CLL
Discover & Search
Research Agent uses searchPapers and citationGraph on 'Alaggio et al. 2022' to map 3291 citing papers on 5th WHO lymphoid classification, revealing CLL-specific updates. exaSearch queries 'WHO CLL immunophenotype 2022' for 50+ related works; findSimilarPapers expands to EuroFlow standardization (van Dongen et al., 2012).
Analyze & Verify
Analysis Agent applies readPaperContent to Alaggio et al. (2022) for CLL criteria extraction, then verifyResponse with CoVe chain-of-verification against Campo et al. (2011). runPythonAnalysis processes ZAP-70 flow data via pandas for IGHV correlation stats; GRADE grading scores evidence from Byrd et al. (2013) trials.
Synthesize & Write
Synthesis Agent detects gaps in cyclin D1-negative CLL mimics via contradiction flagging across Morton et al. (2005) and Alaggio et al. (2022). Writing Agent uses latexEditText for diagnostic flowchart, latexSyncCitations for 10-paper bibliography, and latexCompile for WHO criteria review; exportMermaid generates immunophenotype diagrams.
Use Cases
"Analyze ZAP-70 flow cytometry data correlation with IGHV in CLL cohorts"
Research Agent → searchPapers 'ZAP-70 CLL' → Analysis Agent → runPythonAnalysis (pandas scatterplot of Crespo et al. 2003 data) → statistical p-value and visualization output.
"Draft LaTeX review of 5th WHO CLL classification changes"
Research Agent → citationGraph 'Alaggio 2022' → Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations + latexCompile → formatted PDF with tables.
"Find GitHub repos analyzing WHO CLL incidence datasets"
Research Agent → searchPapers 'Morton 2005 incidence' → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → repo code and HAEMACARE dataset scripts.
Automated Workflows
Deep Research workflow scans 50+ papers from Alaggio et al. (2022) citations for systematic WHO CLL review: searchPapers → citationGraph → GRADE all → structured report. DeepScan applies 7-step analysis to Byrd et al. (2013) with CoVe checkpoints for ibrutinib eligibility under WHO criteria. Theorizer generates hypotheses on IGHV-ZAP-70 from Crespo et al. (2003) and van Dongen et al. (2012).
Frequently Asked Questions
What defines CLL in the 5th WHO classification?
CLL requires >5x10^9/L monoclonal B-lymphocytes with CD5+, CD23+, CD20 dim, sIg weak immunophenotype (Alaggio et al., 2022). Distinguishes from MCL by cyclin D1 negativity and t(11;14) absence.
How do methods assess IGHV status in CLL?
Direct sequencing is gold standard; ZAP-70 flow cytometry acts as surrogate with >20% expression indicating unmutated status (Crespo et al., 2003). EuroFlow panels standardize leukemia immunophenotyping (van Dongen et al., 2012).
What are key papers on WHO lymphoid classification?
Alaggio et al. (2022, Leukemia, 3291 citations) details 5th edition; Campo et al. (2011, Blood, 1957 citations) covers 2008 updates and applications.
What open problems exist in WHO CLL classification?
Standardizing cyclin D1-negative mimics and monoclonal B-cell lymphocytosis progression thresholds. Integrating BTK inhibitor responses like ibrutinib under revised criteria (Byrd et al., 2013).
Research Chronic Lymphocytic Leukemia Research with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching WHO Classification of Lymphoid Neoplasms CLL with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.